Project Grant R41CA261263
- This $255,991 National Science Foundation project grant supports the development of an automated system for rapid analysis of biopsy samples by Amcyt, Inc. The system aims to increase the efficiency and accessibility of fine needle aspiration biopsy procedures through three automated processes: sample smearing, staining, and image capture. This addresses a critical need to improve biopsy analytics and potentially eliminate up to 20% of failed procedures due to sampling errors. By automating...
- The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
- Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...
- The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
- Federal Grant Award Summary Surgivance Inc. received a $978,154 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 18, 2025, with completion anticipated by May 31, 2027. The company is developing a point-of-care digital pathology solution that combines proprietary confocal microscopy hardware with artificial intelligence (AI)-enabled software to deliver rapid, high-resolution three-dimensional (3D) digital...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Macula Vision Systems Inc., a for-profit organization, supports the development of a novel microscopy platform to automate the interpretation of microbiology lab tests performed in hospitals. The project aims to address the shortage of trained lab technicians by engineering a specialized light source, customized camera, and AI-enabled algorithms to analyze...
- The National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded a $300,000 EAGER (Early-Concept Grants for Exploratory Research) project grant to The Research Foundation for The State University of New York (RF SUNY) to establish near-ultraviolet (NUV) coherent anti-Stokes Raman scattering (CARS) microscopy for highly sensitive imaging of native biomolecules. This technology will be applied to develop label-free digital pathology for brain...
- This federal Cooperative Agreement award, issued by the Department of the Interior's Interior Business Center under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384), supports the development of a novel imaging technology called "VISION" that enables real-time, high-resolution intraoperative detection of microscopic residual cancer cells during surgical procedures. The $5,160,920 award to the Regents of the University of California, San Francisco aims to...
- This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
SAME-DAY BREAST PATHOLOGY RESULTS USING OPEN-TOP LIGHT-SHEET MICROSCOPY FOR IMAGE-GUIDED CORE NEEDLE BIOPSIES - ABSTRACT (300 WORDS MAXIMUM) EACH YEAR, OVER 700 WOMEN UNDERGO AN IMAGE-GUIDED CORE NEEDLE BIOPSY (CNB) TO EVALUATE A SUSPICIOUS BREAST FINDING AT THE SEATTLE CANCER CARE ALLIANCE, WITH ONLY ABOUT 30% BIOPSIES YIELDING MALIGNANCY. TYPICAL TURNAROUND TIME FOR DETERMINATION OF THE PRESENCE OR ABSENCE OF CANCER FROM CNBS IS THREE TO FIVE BUSINESS DAYS, AND THIS WAITING TIME CAN LEAD TO AVOIDABLE ANXIETY AND DELAYS IN MANAGEMENT. OUR TEAM HAS PIONEERED THE USE OF OPEN-TOP LIGHT-SHEET MICROSCOPY (OTLS), WHICH IS A SLIDE-FREE FLUORESCENCE IMAGING TECHNIQUE THAT ENABLES RAPID, LARGE AREA SCANNING OF FRESH TISSUE. A PRELIMINARY STUDY USING EXCISED 1 CM2 PIECES OF FRESH BREAST TISSUE SHOWED THAT OTLS IMAGING CAN PROVIDE DIAGNOSTIC QUALITY IMAGES IN UNDER 10 MINUTES. WE HYPOTHESIZE THAT OTLS EVALUATION OF CNB BREAST TISSUE SPECIMENS WILL PROVIDE AN ACCURATE DETERMINATION OF MALIGNANCY VS. NO MALIGNANCY WITHIN 30 MINUTES OF OBTAINING BREAST CORE SPECIMENS. WE WILL TEST THIS HYPOTHESIS BY OPTIMIZING EVALUATION OF CNB SAMPLES WITH OTLS USING BREAST CANCERS THAT HAVE BEEN EXCISED SURGICALLY AND THEN TESTING ITS ACCURACY IN A SMALL CLINICAL TRIAL OF 40 WOMEN. IF SUCCESSFUL, OUR APPROACH COULD ALLOW WOMEN WITH CONCERNING BREAST IMAGING FINDINGS TO HAVE A COMPLETE IMAGING AND PATHOLOGY WORKUP IN THE SAME DAY, LEADING TO REASSURANCE IN THE MAJORITY OF WOMEN AND EARLIER TRIAGE TO APPROPRIATE CARE IN THOSE WITH BREAST CANCER. FURTHERMORE, WIDER APPLICATION OF THIS TECHNOLOGY COULD ALLOW FOR MORE ACCURATE WHOLE-SPECIMEN EVALUATION OF BIOMARKERS OF DISEASE, SUCH AS QUANTIFICATION OF TUMOR INFILTRATING LYMPHOCYTES, AND MORE ELEGANT RADIOLOGY-PATHOLOGY CORRELATION STUDIES THAT COULD ADVANCE THE EMERGING FIELDS OF RADIOMICS AND PATHOMICS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($3) | 2/16/24 | ||
| Not listed | $398.3k | 6/25/21 | ||
| Not listed | $398.3k | 6/25/21 | ||
| Not listed | $398.3k | 6/25/21 |